Pharmicell Co Ltd
Company Profile
Business description
Pharmicell Co Ltd is a biotechnology company, engages in the manufacturing of biopharmaceutical medicines in South Korea. Its biopharmaceutical business engages in the development and manufacture of stem cell therapeutic drugs and stem cell-based cosmetics and others. Its products under development include mesenchymal stem cell products, such as Cellgram_AMI, a heart disease drug; Cellgram_IS and Cellgram_SCI, which are brain/nerve disorder drugs; Cellgram_Lung, a pulmonary disease drug; Cellgram_LC, a liver disease drug; and Cellgram_ED and Cellgram_CLI for the treatment of graft-versus-host disease, kidney transplant, impotence, and critical lower limb ischemia.
Contact
12F Chungho B/D
3-2 Nonhyun-dong Gangnam-gu
Seoul135-010
KORT: +82 234960114
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
161
Stocks News & Analysis
stocks
Higher fair value for undervalued wide moat share
stocks
Fears of deteriorating loan quality sends bank share plummeting
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,026.90 | 46.30 | 0.52% |
| CAC 40 | 8,346.63 | 38.24 | -0.46% |
| DAX 40 | 24,659.19 | 12.03 | -0.05% |
| Dow JONES (US) | 51,876.11 | 44.51 | -0.09% |
| FTSE 100 | 10,476.92 | 31.10 | -0.30% |
| HKSE | 23,026.68 | 354.82 | 1.57% |
| NASDAQ | 25,297.62 | 60.99 | -0.24% |
| Nikkei 225 | 69,468.11 | 107.23 | 0.15% |
| NZX 50 Index | 13,545.56 | 50.32 | 0.37% |
| S&P 500 | 7,354.02 | 3.47 | -0.05% |
| S&P/ASX 200 | 8,823.40 | 46.50 | 0.53% |
| SSE Composite Index | 4,073.90 | 46.64 | 1.16% |